Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approval benefits presbyopic patients
Irvine, CA-The FDA approval of the ViewPoint CK System (Refractec Inc.) for the NearVision conductive keratoplasty (CK) procedure marked a milestone as the first technology to improve near vision in presbyopic patients (See related story from Ophthalmology Times, March 1 issue). The laser-free procedure-which uses radiowaves to reshape the cornea-can be performed in less than 3 minutes with topical anesthesia in the ophthalmologist's office.
Related Videos
Related Content
